About Be Bio
Be Bio is a Healthcare company based in Cambridge (United States) founded in 2020. It operates as a b cell therapies are developed for oncology and rare diseases. Be Bio has raised $356 million across 4 funding rounds from investors including Takeda Pharmaceuticals, RA Capital and Arch Venture Partners. Be Bio offers products and services including B Cell Medicines and Research Platform. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and B-Cell. Its competitors include Immusoft, JW Therapeutics, Walking Fish Therapeutics, Overland Pharmaceuticals and Cellective BioTherapy; 4 of its 5 listed competitors have raised funding.
Company details
Be Bio was founded in 2020 in Cambridge, United States, and operates in the biotechnology sector. Proprietary autologous and allogeneic BeCM platforms are utilized to advance B cell therapies across oncology and rare diseases. Pipeline candidates are progressed in these areas, while the platform is extended to infectious diseases, neurological conditions, and autoimmune diseases.
- Total Equity Funding$356M (USD)
in 4 rounds
- Latest Funding Round$92M (USD), Series C
Jan 2025
- InvestorsTakeda Pharmaceuticals
& 7 more
Products & Services of Be Bio
Be Bio offers a comprehensive portfolio of products and services, including B Cell Medicines and Research Platform.
Engineered treatments for serious diseases like hemophilia B
Tools for advancing B cell therapies through publications
Funding Insights of Be Bio
Be Bio has successfully raised a total of $356M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $92 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $356M
- Total Rounds 4
- Last Round Series C — $92M
- First Round $52M
(Oct 2020)
- Investors Count 8
All 4 funding rounds of Be Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $92M | Series C | – | Nextech Invest | |
| Oct 2024 | $82M | Series B | – | – | |
| Apr 2022 | $130M | Series B | – | Arch Venture Partners | |
| Oct 2020 | $52M | Series A | – | Atlas Venture, RA Capital Management |
8 investors in total: 8 institutional.
Investors in Be Bio
Be Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, RA Capital and Arch Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | – | nextechinvest.com | Zurich, Switzerland | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
Venture capital is directed toward healthcare companies by Longwood Fund. | – | longwoodfund.com | Boston, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Be Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Be Bio
42 people are tracked at Be Bio (15 in leadership, 4 in board & advisors, 23 in team).
| Name | Role | Group |
|---|---|---|
Andria Albertini | Vice President, Finance & Accounting | Leadership |
Carlos Candido | Vice President, External Manufacturing & Supply Chain | Leadership |
Sean Marnane | Senior Director, External Manufacturing And MSAT | Leadership |
Mark Lalli | Director, Process Development | Leadership |
Suha Patel | Senior Vice President - Commercial And Franchise Strategy | Leadership |
Viera Muzithras | Vice President | Leadership |
Joanne Smith-Farrell | CEO & Director | Leadership |
Peter Wang | Vp, Business Development & Strategy | Leadership |
Jeff Autenrieth | Talent Partner | Leadership |
Rick Morgan | Chief Scientific Officer | Leadership |
Anja Hohmann | Senior Director, Cell Engineering | Leadership |
Deborah Lloyd | Vice President, Clinical Operations | Leadership |
Cleo Isaacs | Associate Director | Leadership |
Sean Arlauckas | Senior Director, B Cell Platform | Leadership |
Rashmi Korke-Kshirsagar | Senior Vice President, Technical Development And CMC Strategy | Leadership |
Rich James | Founder | Board & advisors |
Aleks Radovic-Moreno | Co-Founder & Director | Board & advisors |
Frances Eun-Hyung Lee | Scientific Advisor | Board & advisors |
Laura Tadvalkar | Board Director, Former Board Observer | Board & advisors |
Jordan Smelker | Principal Engineer | Team |
22 more people are available in the full profile.
Complete people profiles for Be Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Be Bio
3 dated milestones of Be Bio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Be Bio is founded.
- Funding First funding round of $52.0M.
- Funding Latest funding round, Series C, of $92.0M.
Competitors of Be Bio
Be Bio has 5 listed competitors in our database, 4 of them funded. They include Immusoft, JW Therapeutics, Walking Fish Therapeutics, Overland Pharmaceuticals and Cellective BioTherapy, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| immusoft.com | 2009 | Seattle, United States | $44.13M | – | B cells are programmed as biofactories for therapeutic protein delivery. | |
| jwtherapeutics.com | 2016 | Shanghai, China | $195.55M | – | Cell immunotherapy products are developed for cancer treatment. | |
| walkingfishtx.com | 2019 | San Francisco, United States | $123M | – | Cell-based therapeutics for cancer and immunological disorders are developed. | |
| overlandpharma.com | 2020 | Boston, United States | – | – | - | |
| cellectivebiotherapy.com | 2015 | Durham, United States | $2.5M | – | B cell-based therapies are developed for autoimmunity, immunodeficiency, and cancers. |
Detailed competitors of Be Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Be Bio
The website of Be Bio (be.bio) receives about 5.8K visits a month.
- Monthly visits5.8K
▼ 7.2% vs previous month
Top companies in Cell Therapy
10 companies that operate in the same segment as Be Bio (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Be Bio
Complete news archive for Be Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Be Bio
Be Bio was founded in 2020.
Be Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Be Bio is a funded company, having raised a total of $356M across 4 funding rounds to date. The company's 1st funding round was a Series A of $52M, raised on Oct 2020.
Be Bio was founded in 2020 in Cambridge, United States, and operates in the biotechnology sector. Proprietary autologous and allogeneic BeCM platforms are utilized to advance B cell therapies across oncology and rare diseases. Pipeline candidates are progressed in these areas, while the platform is extended to infectious diseases, neurological conditions, and autoimmune diseases.
Be Bio's top competitors include Immusoft, JW Therapeutics and Walking Fish Therapeutics.
Be Bio offers B Cell Medicines and Research Platform.
Be Bio has 8 investors. Key investors include Takeda Pharmaceuticals, RA Capital, Arch Venture Partners, Atlas Venture, and Bristol-Myers Squibb.